Safety and efficacy of intravenous bimagrumab in inclusion body myositis

Lancet published the latest results to Bimagrumab from Novartis in the RESILIENT study.

Between Sept 26, 2013, and Jan 6, 2016, 251 participants were enrolled to the study, of whom 63 were assigned to each bimagrumab group and 62 were allocated to the placebo group.

For more Details visit Lancet

Clinical Trials
Bimagrumab

News about Myositis

Författare: Liz

Att acceptera vad som händer och låt trollen i ljuset, kanske du borde att tro mer på dig själv

3 reaktioner till “Safety and efficacy of intravenous bimagrumab in inclusion body myositis”

    1. Hello Hanna,

      no Bimagrumab is in clinical development at Novartis and is not yet available on market. The antibody was developed by MorphoSys in Munich.

      Activin type II receptors are intended for the treatment of muscle disorders associated with muscle atrophy.

      #BYM338

Kommentarer inaktiverade.